Targeting of PI3K-a and CDK4/6 kinases in mantle cell lymphomas with dual kinase inhibitor ON 123300-lactate

被引：0
|
作者：
Akula, Balireddy [1 ]
Divakar, Saikrishna A. [2 ]
Bharathi, Vijaya E. [2 ]
Mallireddigari, Muralidhar R. [1 ]
Subbaiah, D. R. C. Venkata [2 ]
Pallela, Venkat R. [1 ]
Billa, Vinay K. [2 ]
Cosenza, Stephen C. [2 ]
Reddy, E. Premkumar [2 ]
Reddy, M. V. Ramana [2 ]
机构：
[1] Onconova Therapeut Inc, Dept Med Chem, Newtown, PA 18940 USA
[2] Icahn Sch Med Mt Sinai, Dept Med Chem, New York, NY 10029 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
493-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO SELECTIVE PI3K-A, -B, -Δ INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)
    Zoellner, A.
    Arnd, J.
    Hutter, G.
    Zimmermann, Y.
    Hiddemann, W.
    Dreyling, M.
    HAEMATOLOGICA, 2015, 100 : 551 - 551
  • [22] Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
    Lee, Cha Len
    Cremona, Mattia
    Farrelly, Angela
    Workman, Julie A.
    Kennedy, Sean
    Aslam, Razia
    Carr, Aoife
    Madden, Stephen
    O'Neill, Brian
    Hennessy, Bryan T.
    Toomey, Sinead
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [23] Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
    Lukoseviciute, Monika
    Maier, Henrietta
    Poulou-Sidiropoulou, Eleni
    Rosendahl, Erika
    Holzhauser, Stefan
    Dalianis, Tina
    Kostopoulou, Ourania N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma
    Profitos-Peleja, Nuria
    Ribeiro, Marcelo L.
    Silverstein, Adar Makovski
    Cosenza, Stephen
    Roue, Gael
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Targeting the mitotic kinase NEK2 potentiates CDK4/6 inhibitor efficacy in breast cancer
    Bobbitt, Jessica R.
    Cuellar-Vite, Leslie
    Bryson, Benjamin
    Weber-Bonk, Kristen
    Keri, Ruth
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor.
    Dai, Kang
    Keegan, Kathleen
    Li, Zhihong
    Ji, Ma
    Li, Gong
    Eksterowicz, John
    Suzanne, Coberly
    Hollenback, David
    Weidner, Margret
    Huard, Justin
    Liang, Lingming
    Alba, Grace
    Orf, Jessica
    Lo, Mei-Chu
    Zhao, Sharon
    Ngo, Rachel
    Chen, Ada
    Liu, Lily
    Carlson, Timothy
    Mcgee, Lawrence R.
    Medina, Julio
    Kamb, Alexander
    Vlickramasinghe, Dineli
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [27] Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
    Liu, Qiang
    Cai, Zijie
    Wang, Jingru
    Li, Yudong
    Wong, Lok Lam
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
    Zijie Cai
    Jingru Wang
    Yudong Li
    Qianfeng Shi
    Liang Jin
    Shunying Li
    Mengdi Zhu
    Qi Wang
    Lok Lam Wong
    Wang Yang
    Hongna Lai
    Chang Gong
    Yandan Yao
    Yujie Liu
    Jun Zhang
    Herui Yao
    Qiang Liu
    Science China Life Sciences, 2023, 66 : 94 - 109
  • [29] Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
    Cai, Zijie
    Wang, Jingru
    Li, Yudong
    Shi, Qianfeng
    Jin, Liang
    Li, Shunying
    Zhu, Mengdi
    Wang, Qi
    Wong, Lok Lam
    Yang, Wang
    Lai, Hongna
    Gong, Chang
    Yao, Yandan
    Liu, Yujie
    Zhang, Jun
    Yao, Herui
    Liu, Qiang
    SCIENCE CHINA-LIFE SCIENCES, 2023, 66 (01) : 94 - 109
  • [30] Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
    Zijie Cai
    Jingru Wang
    Yudong Li
    Qianfeng Shi
    Liang Jin
    Shunying Li
    Mengdi Zhu
    Qi Wang
    Lok Lam Wong
    Wang Yang
    Hongna Lai
    Chang Gong
    Yandan Yao
    Yujie Liu
    Jun Zhang
    Herui Yao
    Qiang Liu
    Science China(Life Sciences), 2023, 66 (01) : 94 - 109
12345